Difference between hizentra and cuvitru?

What conditions do hizentra and cuvitru treat?

Hizentra and Cuvitru are subcutaneous immunoglobulin (Ig) G products used to treat primary immunodeficiency (PID). They are alternatives to intravenous (IV) Ig infusions and are administered via injections under the skin. Both products contain human IgG antibodies, which help replace missing or low levels of antibodies in the body. Hizentra is marketed by ViroPharma (now part of Shire), and Cuvitru is developed and marketed by Biotest.

Key similarities between hizentra and cuvitru

Both Hizentra and Cuvitru contain IgG antibodies and have similar mechanisms of action, providing essential antibody replacement for patients with PID. They can be used to treat multiple primary immunodeficiencies, including IgG subclass deficiencies and chronic lymphatic leukemia (CLL).

Notable differences between hizentra and cuvitru

Hizentra [1] comes in a 20% (500 mg/mL) IgG concentration, which allows patients to take smaller volumes and have fewer injections over time. On the other hand, Cuvitru [2] is available in 11%, 15%, 18%, 20% (100 mg/mL, 130 mg/mL, 150 mg/mL, and 200 mg/mL), and 25% (300 mg/mL) concentrations. Cuvitru is also the first commercial Ig product with a 25% concentration, which may reduce treatment costs by requiring smaller volumes.

When do patents expire for hizentra and cuvitru?

Patents have a significant impact on the market availability and cost of pharmaceutical products. The patent expiration for Cuvitru [3] is expected to have a later date compared to Hizentra [4]. When the patents expire, generic versions of the medications may become available, affecting the market and pricing of these products.

Patient concerns about hizentra and cuvitru

According to patients, both Hizentra and Cuvitru are effective in treating their PID. However, some patients have raised concerns about potential side effects, such as injection site reactions and allergic reactions [5]. It is essential to discuss any concerns or questions with a healthcare professional.

Sources:

[1] http://www.drugpatentwatch.com/product/1000004/hizentra/
[2] http://www.drugpatentwatch.com/product/1000058/cuvitru/
[3] https://www.drugpatentwatch.com/expiration/1000058
[4] https://www.drugpatentwatch.com/expiration/1000004
[5] https://www Patient forums (search)